a phase ii study of i-sabr in early or recurrent nsclc
Published 10 months ago • 117 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
0:51
assessing i-sabr in early or recurrent non-small cell lung cancer
-
1:08
the future of i-sabr in lung cancer
-
1:51
outcomes of i-sabr in lung cancer
-
1:00
combining sabr and immunotherapies for nsclc
-
11:53
insight 2: a phase ii study of tepotinib plus osimertinib in met-amplified nsclc
-
4:17
how does lung cancer affect the body?
-
6:23
radiotherapy treatment
-
59:08
session 2 - sbrt/srs small-field dosimetry
-
1:13
phase ii study of durvalumab for patients with nsclc
-
1:22
real-world dfs as a predictor of os in resected early-stage non-small cell lung cancer
-
1:53
assessing targeted therapies in early stage nsclc
-
6:23
adaura trial; early stage non–small cell lung cancer
-
2:00
updated data from phase 2 study of alectinib in alk–positive non–small–cell lung cancer
-
19:24
debate: optimal approach for stage i nsclc - sbrt
-
3:44
immunotherapy as combination and neoadjuvant therapies in nsclc
-
1:05
efficacy of mobocertinib in patients previously treated with tkis
-
1:30
a shifting paradigm: lung cancer
-
5:04
sport study: second primary lung cancer
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
2:20
sabr improves outcomes for stage 1 lung cancer
-
2:43
targeted therapy for early-stage lung cancer
-
8:14
phase ii study of the hsp90 inhibitor ganetespib as monotherapy in patients with advanced nsclc